Background: Cross resistance between androgen-receptor targeting therapies(ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) fortreatment of metastatic castration-resistant prostate cancer (mCRPC) may affectresponses to second ART (ART2). Objective: To establish treatment duration and prostate-specific antigen (PSA)response of ART2 in real-world mCRPC patients treated with or without otherlife-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) betweenART1 and ART2.
Design, setting, and participants: Castration-resistant prostate cancer patients,diagnosed between 2010 and 2016 were retrospectively registered in Castra-tion-resistant Prostate Cancer Registry (CAPRI). Patients treated with both ARTswere clustered into two subgroups: ART1 > ART2 or ART1 > LPD > ART2.

Castration-resistant prostate cancer, Androgen-receptor targeting agents
dx.doi.org/10.1016/j.euo.2019.09.005, hdl.handle.net/1765/135464
European Urology Oncology
Radboud University Nijmegen Medical Centre

Kuppen, M.C.P, Westgeest, H.M, van den Eertwegh, A.J.M, van Moorselaar, R.J.A, van Oort, I.M, Coenen, J.L.L.M, … Gerritsen, W.R. (2019). Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer. European Urology Oncology, S2588-9311. doi:10.1016/j.euo.2019.09.005